ERBB2 and breast cancer: The early identification of non-responding BC patients in neoadjuvant settings is crucial for optimizing treatment strategies and improving patient outcomes, particularly for aggressive TNBC and HER2+ BC subtypes, since achieving pCR in these subtypes has been substantially associated with improved long-term outcomes [74,75].